Back to search
FDAFDA · Food and drugs·Recall number D-0440-2017

Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in a 100 mL bottle, Rx only, Manufactured for: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-4150-73

Published February 1, 2017 · Recall initiated: December 21, 2016

Summary

FDA records drug Class II recall D-0440-2017, published February 1, 2017 and initiated December 21, 2016. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 133,601 bottles; Lot: Lot # 35432507A, 35434914A, 35435798A, 35437490A, Exp 9/19. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotency: due to a low, out of specification test result for assay during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
United States and Puerto Rico
Lot
Lot # 35432507A, 35434914A, 35435798A, 35437490A, Exp 9/19
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in a 100 mL bottle, Rx only, Manufactured for: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-4150-73 recalled?

Yes. FDA published recall D-0440-2017 on February 1, 2017. Reported hazard: Subpotency: due to a low, out of specification test result for assay during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter